GE HEALTHCARE
SpecialtyGE HEALTHCARE is a specialty pharmaceutical company focused on Neurology, Cardiovascular, Infectious Disease. Key products include VIZAMYL.
FDA Novel Drug Designations
(2020)See 1 novel approval →
GE HEALTHCARE at a Glance
- Fast trial execution (13 months median completion)
Upcoming FDA Decisions
Full Calendar →GE HEALTHCARE's Key Drugs
GE HEALTHCARE's core commercial portfolio centers on CLARISCAN, VIZAMYL, CERIANNA, spanning Neurology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
GE HEALTHCARE's Recent FDA Approvals
New NDA/BLA approvals for GE HEALTHCARE over the last two years — novel drugs only, excluding generics and label supplements.
GE HEALTHCARE's Therapeutic Areas
GE HEALTHCARE's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 17 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GE HEALTHCARE's Top Competitors
GE HEALTHCARE's closest competitors by therapeutic-area and drug-target overlap include Merck, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GE HEALTHCARE Pipeline Snapshot
GE HEALTHCARE has 23 active clinical programs from ClinicalTrials.gov — 5 Phase 3, 9 Phase 2 and 9 Phase 1.
Phase 3 Readout Calendar Pro
2 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CLARISCAN leads revenue
- • 3 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 9/11 completed
- • Speed: 13 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges